Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.

Scientific microscope with visual representation of DNA helix

Trethera To Participate in Panel Discussion and Research Poster Competition At Los Angeles Bioscience Ecosystem Summit 2025

April 22, 2025

Los Angeles, April 22, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announces a forthcoming panel discussion and poster presentation at the 7th Annual Los Angeles Bioscience Ecosystem Summ

Read More 

Trethera Treats a Late-Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis (ALS) Patient with TRE-515



March 31, 2025

Los Angeles, March 31, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through first-in-class drugs, announced clinical results from treating a patient with ALS (amyotrophic lateral sclerosis, also known as Lo

Read More 

Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control Immune Cell Activation That Causes Multiple Sclerosis Symptoms in Mice



February 25, 2025

Los Angeles, February 25, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through first-in-class drugs, announced research results in the peer-reviewed journal Immunology demonstrating that TRE-515 selectively

Read More 

Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress



January 15, 2025

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the Crohn’s & Colitis Co

Read More 

Trethera Announces Presentation at the Rare Neuroimmune Disorders Symposium Annual Meeting



October 15, 2024

Los Angeles, October 15, 2024 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming presentation at the 7th Annual Meeting of the R

Read More 